Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomas in the skin and other organs, including brain, heart, lung, kidney and bones. TSC is caused by mutations in TSC1 and TSC2. Here, we present the TSC1 and TSC2 variants identified in 168 Danish individuals out of a cohort of 327 individuals suspected of TSC. A total of 137 predicted pathogenic or likely pathogenic variants were identified: 33 different TSC1 variants in 42 patients, and 104 different TSC2 variants in 126 patients. In 40 cases (24%), the identified predicted pathogenic variant had not been described previously. In total, 33 novel variants in TSC2 and 7 novel variants in TSC1 were identified. To assist in the classification of 11 TSC2 variants, we investigated the effects of these variants in an in vitro functional assay. Based on the functional results, as well as population and genetic data, we classified 8 variants as likely to be pathogenic and 3 as likely to be benign.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7303179PMC
http://dx.doi.org/10.1038/s41598-020-66588-4DOI Listing

Publication Analysis

Top Keywords

tsc1 tsc2
12
tsc2 variants
12
variants
9
tuberous sclerosis
8
sclerosis complex
8
variants identified
8
predicted pathogenic
8
novel variants
8
tsc2
6
tsc1
5

Similar Publications

Background: Tuberous sclerosis complex (TSC) is an autosomal dominant genetic disorder characterized by mutations in the TSC1 and TSC2 genes, leading to the dysregulation of the mammalian target of rapamycin (mTOR) pathway. This dysregulation results in the development of benign tumors across multiple organ systems and poses significant neurodevelopmental challenges. The clinical manifestations of TSC vary widely and include subependymal giant cell astrocytomas (SEGAs), renal angiomyolipomas (AMLs), facial angiofibromas (FAs), and neuropsychiatric conditions such as autism spectrum disorder (ASD).

View Article and Find Full Text PDF

Tuberous sclerosis complex (TSC) is a rare genetic disorder characterized by the formation of benign tumors in various organs, particularly in the central nervous system. We aimed to delineate the molecular profile of Turkish individuals diagnosed with TSC by analyzing the TSC1 and TSC2 genes using next-generation sequencing (NGS). Sophia Genetics' Sophia Inherited Disease Panel was used to perform NGS on 22 individuals diagnosed with TSC and to identify pathogenic variants in the TSC1 and TSC2 genes.

View Article and Find Full Text PDF

Tuberous sclerosis complex (TSC) is an autosomal dominant disorder caused by mutations in either the or genes. Though TSC causes the formation of nonmalignant tumors throughout multiple organs, the most frequent causes of mortality and morbidity are due to neurological complications. In two-thirds of cases, TSC occurs sporadically and pathogenic variants are approximately three times more prevalent than pathogenic variants.

View Article and Find Full Text PDF

Molecular and Functional Assessment of and in Individuals with Tuberous Sclerosis Complex.

Genes (Basel)

November 2024

Human Genome and Stem Cell Research Center, Department of Genetics and Evolutionary Biology, Instituto de Biociências, Universidade de São Paulo, São Paulo 05508-090, Brazil.

Article Synopsis
  • * A genetic diagnosis of TSC aids in confirming the clinical diagnosis and helps in managing care and monitoring patients.
  • * In a study of 116 individuals, 91% had pathogenic DNA alterations in TSC-related genes, with detailed functional assessments revealing novel variants impacting TSC protein activity.
View Article and Find Full Text PDF
Article Synopsis
  • Pathogenic mutations in genes associated with tuberous sclerosis complex (TSC) affect various types of kidney tumors like eosinophilic solid and cystic renal cell carcinoma (ESC RCC) and oncocytic tumors.
  • A study validated a TSC2 immunohistochemistry (IHC) assay on tissues from renal tumors to assess the presence of TSC2 mutations, achieving high predictive values for diagnosing these tumors.
  • The findings highlight that TSC2 IHC can help identify renal tumors linked to TSC/mTOR pathway mutations, supporting its use in diagnostic processes.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!